DARE Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
152.5K
-85.1%
1.0M
+45155.3%
2.3K
+110.7%
-21172
-183.3%
25.4K
Cost of Revenue
242.3K
-18.1%
295.8K
0
0
0
Gross Profit
-89870
-112.3%
727.9K
+32078.5%
2.3K
+110.7%
-21172
-183.3%
25.4K
Operating Expenses
2.9M
+32.3%
2.2M
-40.1%
3.7M
-3.5%
3.8M
-17.4%
4.6M
R&D
660.5K
+6.2%
622.0K
-47.1%
1.2M
-17.7%
1.4M
-37.8%
2.3M
SG&A
2.2M
+42.6%
1.6M
-36.9%
2.5M
+5.1%
2.4M
+3.0%
2.3M
Operating Income
-2998898
-103.8%
-1471268
+59.9%
-3672148
+4.1%
-3827800
+16.4%
-4581118
EBITDA
-2444255
-160.9%
-936873
+70.6%
-3190242
+5.3%
-3367725
+23.6%
-4405476
Net Income
-2999889
-108.1%
-1441718
+59.5%
-3562766
+11.3%
-4016483
+8.3%
-4378307
EPS (Basic)
$-0.21
-110.0%
$-0.10
+64.3%
$-0.28
+37.8%
$-0.45
+10.0%
$-0.50
EPS (Diluted)
$-0.21
-110.0%
$-0.10
+64.3%
$-0.28
+37.8%
$-0.45
+10.0%
$-0.50
Shares (Diluted)
14.5M
+1.3%
14.3M
+12.3%
12.8M
+43.8%
8.9M
+1.3%
8.8M
Dare Bioscience (DARE) โ€” Financials